[3]宫春飞.慢性粒细胞白血病急性红白血病变1例[J].实用医药杂志, 2011, 28(9):1.DOI:CNKI:SUN:QEYY.0.2011-09-044. [4]Haematolymphoid Tumours WHO Classification of Tumours, 5th Edition. [5]刘延方,董慧,孙慧,等.Ph+急性淋巴细胞白血病与慢性...
[3] Derderian P M, Kantarjian H M, Talpaz M, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis[J]. Am J Med. 1993, 94(1): 69-74. [4] Cortes J, Kim D W, Ra...
often via an accelerated phase (AP). Disease progression is defined by the blast cell count in the peripheral blood as of 10–20 % in AP and >20 % in BC. The phenotype of BC can be myeloid or lymphoid or, in rare cases, both. Myeloid-BC is predominantly observed (on a 2:...
CD62L downregulation may impair effector CTL immune responses in CML patients at diagnosis and abrogate antileukemic immune control because CD62L is critical in controlling the traffic of T cells to secondary lymphoid tissues and priming by APCs. Sopper et al56 have reported decreased CD62L ...
(95% CI: 4.7%; 7.1%). Most BC occurred in the first two years, but some continued to occur later during the entire observation time (Figure 4). Median survival after BC was 7.9 months across all treatment arms. Thirty-eight patients had myeloid, 28 lymphoid BC, in 21 patients the ...
High-density single nucleotide polymorphism arrays have recently pinpointed deletions of the Ikaros gene as a critical 1981 Leukemia Chronic myeloproliferative disorders compared NCP Cross et al 1982 event in lymphoid transformation of CML as well a Ph chromosome-positive ALL.142 degree of activity ...
The patient was thought to have "lymphoid" types of leukemic cells in BP, with an extramedullary origin of such cells, particularly in lymph nodes, playing a major role in the genesis of BP. The reported cases of near-haploidy with Ph1-positive CML and those with constitutional translocations...
Of note, elevated CD123 expression was detected in CD34+ cells of patients not only in myeloid but also in lymphoid BC, consistent with high CD123 levels in B-cell acute lymphocytic leukemia (ALL), including Ph+ ALL.44,45 Another strategy targeting CD123, diphtheria toxin–conjugated IL-3,...
(70–95% inhibition) of imatinib/dasatinib-sensitive and -resistant (T315I) p210 and p190 BCR/ABL-expressing myeloid and lymphoid progenitor cell lines (Ph1 K562, 32D-p210BCR/ABL, 32D-p210(T315I)BCR/ABL and BaF3-p190BCR/ABL), respectively, and of primary bone marrow CML-BCCD34+ (n=...
In CML-BC patients, the most frequent grade 3-4 nonhematologic adverse events were pneumonia (11%), pyrexia (6%), diarrhea (4%), and asthenia (4%). Contributing Writer Investigator Assessment of Best Response to Nilotinib in Patients With CML-BC Myeloid Lymphoid Unknown Type (n = 87) (...